Kymera IPO Presentation Deck

MYD88 mutation drives differentiation and proliferation in subset of B cell lymphomas Selective kinase inhibitors do not affect viability Degraders are effective in this context IMiDs downregulate IRF4, increasing IFN signaling and further suppressing NFkB activation IRAKIMID A Combo in a Single Molecule Inhibiting both MYD88 and IRF4-dependent NFkB and activating IFN signaling drive cell death in MYD88-mutant lymphomas and leads to full and durable responses in vivo KYMERA Indications/Timeline MYD88-mutant Diffuse Large B Cell Lymphoma Current: Preclinical development Expected IND submission: 2H 2021 Expected P1: 2H 2021 IRAK4 Degrader S JNK IL-1R UVERDAFTAND GRARATARS RAK IRAK AP1 Pathway KKK Pathway NFKB Pathway 8 Cell Receptor CL10 TK CD79A/B* IRFA PROLIFERATION & SURVIVAL Adapted from Yang et al. (2012) Cancer Cell 21, 6. pp723-737 *Oncogenic driver mutations IRAK4+ Ikaros/Aiolos IMIDS Baros Nucles IFN IFNAR1/2 IFN Pathway

View entire presentation